Fulcrum Therapeutics (NASDAQ:FULC) Now Covered by Analysts at Morgan Stanley

Morgan Stanley began coverage on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a research report sent to investors on Monday morning, BenzingaRatingsTable reports. The firm issued an overweight rating and a $29.00 target price on the stock.

Separately, Bank of America began coverage on Fulcrum Therapeutics in a research note on Monday. They issued a buy rating and a $19.00 price target for the company.

Shares of FULC opened at $9.26 on Monday. Fulcrum Therapeutics has a 52 week low of $9.25 and a 52 week high of $15.94.

In other news, major shareholder 6 Dimensions Capital, L.P. purchased 118,750 shares of the company’s stock in a transaction dated Monday, July 22nd. The stock was bought at an average cost of $16.00 per share, for a total transaction of $1,900,000.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Mark J. Levin purchased 81,250 shares of the company’s stock in a transaction dated Monday, July 22nd. The stock was purchased at an average price of $16.00 per share, with a total value of $1,300,000.00. The disclosure for this purchase can be found here.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia.

Featured Article: Dollar Cost Averaging

Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.